The renin-angiotensin-aldosterone system makes a critical contribution to body fluid homeostasis, and abnormalities in this endocrine system have been implicated in certain forms of hypertension. The peptide hormone angiotensin II (AngII) regulates hydromineral homeostasis and blood pressure by acting on both peripheral and brain targets. In the brain, AngII binds to the angiotensin type 1 receptor (AT1R) to stimulate thirst, sodium appetite and both arginine vasopressin (AVP) and oxytocin (OT) secretion. The present work used an experimental model of endogenous AngII to examine the role of p44/42 mitogen-activated protein kinase (MAPK) as a signalling mechanism to mediate these responses. Animals were given a combined treatment of furosemide and a low dose of captopril (furo/cap), a diuretic and an angiotensin converting enzyme inhibitor, respectively, to elevate endogenous AngII levels in the brain. Furo/cap induced p44/42 MAPK activation in key brain areas that express AT1R, and this effect was reduced with either a centrally administered AT1R antagonist (irbesartan) or a p44/42 MAPK inhibitor (U0126).
Introduction
The renin-angiotensin-aldosterone system promotes body fluid homeostasis by coordinating physiological and behavioural responses to correct fluid perturbations (1, 2) .
Hypotensive and hypovolemic events prompt the release of the enzyme renin from the kidneys, which initiates a catalytic cascade that ultimately elevates blood levels of the hormone angiotensin II (AngII) (3) . Peripherally, AngII constricts blood vessels to support blood pressure. Circulating AngII binds to brain receptors in the subfornical organ (SFO), organum vasculosum of the lateral terminalis (OVLT), brain regions with an incomplete blood-brain barrier. In addition, AngII produced locally by the brain renin-angiotensin system acts on relays in the median pre-optic nucleus (MNPO), paraventricular nucleus of the hypothalamus (PVN) and supraoptic nucleus (SON) (4) . Acting upon these central nuclei, AngII prompts thirst, sodium appetite (5, 6) , and both arginine vasopressin (AVP) and oxytocin (OT) secretion (7) . While the physiological actions of AngII are well known, our understanding of its cellular actions is incomplete.
The central actions of AngII are mediated by the angiotensin type 1 receptor (AT1R), which belongs to the super family of G protein coupled receptors and associates with Gq to trigger inositol 1,4,5-triphosphate (IP3) production and Ca 2+ mobilization (8, 9) . In vitro research uncovered a parallel signal transduction pathway that phosphorylates MAPK Kinase (MEK), which activates mitogen-activated protein kinase (MAPK) (10) , including the p42 and p44
isoforms, also referred to as extracellular signal-regulated kinase 1 and 2. In turn, p44/42 MAPK provokes a variety of downstream changes in cellular activity, such as changes in gene expression (11) (12) (13) . Although the majority of studies examining AT1R-induced p44/42 MAPK activation were performed in vitro, p44/42 MAPK activation also occurs in the SFO and PVN after a systemic AngII injection (14) . As these AT1R signalling molecules were detected in the brain, researchers have begun to investigate their role in the neural actions of AngII.
A previous study employed signalling selective AT1R ligands and inhibitors to reveal that the inositol triphosphate (IP3) branch of AT1R signal transduction mediates thirst, whereas the p44/42 MAPK signalling pathway mediates sodium appetite (15, 16) . This finding was novel and intriguing; however, it remained unclear whether the result reflected a normal physiological process or a pharmacological phenomenon based on exogenously administered AngII. Therefore, to establish the physiological significance of AngII-induced p44/42 MAPK on sodium appetite, we exploited a preparation for endogenous AngII-induced sodium appetite (17) . More specifically, a combined treatment of furosemide and a low dose of captopril (furo/cap), a loop diuretic and an inhibitor of angiotensin converting enzyme (ACE) inhibitor, respectively, elevates brain levels of AngII. The low dose of captopril blocks the conversion of diuresis-provoked angiotensin I to AngII in the periphery, but still allows conversion in circumventricular organs, which contain very high levels of ACE in comparison to the periphery (18) . The high level of endogenous AngII production in the brain elicits rapid and robust thirst and sodium ingestion (19) .
We used this model to test the hypothesis that p44/42 MAPK phosphorylation mediates sodium, but not water, ingestion induced by endogenous AngII production.
Given the myriad actions of AngII in the brain, it is important to consider the signalling pathways involved in other AngII-induced effects, such as neuroendocrine responses. In addition to its effects on water and sodium ingestion, central AngII is a potent stimulus for AVP and OT secretion (20) . While AVP promotes renal water reabsorption, OT increases renal sodium excretion and centrally inhibits sodium appetite (21) (22) (23) . AT1R-expressing neurones in the SFO send axonal projections to the neurosecretory PVN and SON, where AVP and OT neuronal activity is increased to hormone release from the neurohypophysis (24) . We addressed the role of p44/42 MAPK signalling in AngII-induced AVP and OT by measuring plasma levels of the neurohypophysial hormones after either furo/cap treatment or icv AngII in the presence of an AT1R antagonist or MEK inhibitor. Overall, our experiments better define the participation of p44/42 MAPK signalling in the regulation of fluid balance.
Materials and Methods

Animals
Adult male Sprague-Dawley rats (n = 83) that weighed between 225-250 g were obtained The brain tissue samples were sonicated three times for one second (incubated on ice between bursts) followed by centrifugation at 14,000 rpm at 4C for 10 minutes. Supernatant was collected and a protein assay was performed on five microliters of each sample. Based on the protein levels detected by Bicinchoninic Acid Assay, appropriate amounts of lysis buffer, sample, and sample diluent were mixed for each sample. This mixture (100 µl) was loaded into corresponding wells in both the Total and Phospho p44/42 MAPK Sandwich ELISA kits. The ELISA was performed according to the protocol provided by each kit.
Behavioural Study
For behavioural experiments, rats were removed from their home cages approximately one hour before the onset of the dark phase. The rats were weighed and then placed in individual wire mesh-bottomed cage equipped with a funnel and calibrated tube for the collection of urine, and with two 25-ml bottles available for drinking tap water and 1.5% saline, each marked with 0.2 ml graduations. The rats were allowed to acclimate for one hour before the experiment began. After the last drug treatment was given, water, saline, and urine levels were measured at 15 min intervals for the first hour and then at 30 min intervals for the remaining time. Experiment 2B. The goal of the second behavioural experiment was to examine the role of p44/42 MAPK activation on water intake in the absence of sodium ingestion. The animals were treated with either vehicle or U0126 icv followed 15 minutes later by furosemide, and 10 minutes later by captopril in a crossover design. Rather than being presented with two bottles, as in the first experiment, animals were presented with a single bottle containing tap water. Water intake was monitored for the next 90 minutes.
AVP and OT Secretion
Experiment 3A. Rats were pretreated centrally with either vehicle, irbesartan, or U0126, followed by either vehicle or furo/cap, sc as described above. Thirty minutes after the captopril injection rats were rapidly decapitated and trunk blood was collected into 10 ml BD Vacutainer blood collection heparinised glass tubes on ice (Franklin Lakes, NJ). The thirty-minute time point was chosen based on the emergence of diuresis and drinking behaviour in our initial furo/cap studies. Additionally, the ELISA study showed that U0126 effectively inhibited p44/42 MAPK activation at this time point. Previous research examined a ninety-minute time point after furo/cap treatment, but did not observe increases in oxytocin (19) . extracted plasma was 0.5 pg/ml and 0.25 µU/ml, respectively. The AVP antiserum (R-4) displayed < 1% cross-reactivity with OT, and the OT antiserum exhibited < 1% cross-reactivity with AVP.
Experiment 3B. Rats were assigned to one of the following pretreatment groups: vehicle or U0126 (1mM) followed 15 minutes later by AngII (20 ng) icv. Two or fifteen minutes after the last icv injection, rats were rapidly decapitated and their trunk blood was collected. The two-and fifteen-minute time points were based on the emergence of drinking behaviour in previous exogenous AngII studies and selected to establish the range of neurohypophysial hormone levels in the plasma after the treatments. Previous studies used a 90-second time point and observed increases in plasma vasopressin (27) . The protocol described in Experiment 3A was then followed to measure AVP and OT levels.
Statistical Analysis
Data are presented as the mean ± the standard error of the mean. For the behavioural studies, comparisons were made between the treatment conditions and over time using repeated measure analysis of variance (two-way ANOVA; time point x treatment). For the p44/42 MAPK ELISA and AVP/OT radioimmunoassay results, comparisons were made between the treatment groups (one-way ANOVA). When warranted, planned comparison post-hoc t-tests were performed. All hypothesis tests used =0.05 as the criterion level of significance. Statistical analyses were conducted using Prism 2.0 software (La Jolla, CA).
Results
Furo/cap treatment activates p44/42 MAPK in the brain
In Experiment 1, rat brain punches were collected from coronal slices for several brain regions, namely, OVLT, SFO, PVN SON and primary somatosensory cortex as a control brain region (depicted in Figure 1 ). As shown in Figure 2A , total p44/42 MAPK levels between all of the treatment groups in the OVLT/SFO were not different (ANOVA F(5,19) = 0.5, p>0.05). As shown in Figure 2C , the control brain region S1 had similar levels of p44/42 total The role of p44/42 MAPK in furo/cap-induced water and sodium ingestion Consistent with previous work (19) , the furo/cap protocol produced a rapid diuresis and prompt water and sodium ingestion (as shown in Figure 3) . A two-way ANOVA established a strong main effect of furo/cap treatment on urine output (F(1, 112) = 72.4, p<0.0001). Animals that received furo/cap treatment excreted significantly more urine during the three hours after treatment than controls (13.6 ± 1.1 versus 2.9 ± 0.5 ml, p<0.001). This increase in urine output was first significant within 15 minutes of treatment (p<0.01). These animals also drank water robustly in response to the furo/cap treatment compared with controls (F(1,112) = 23.5, p<0.001;
7.8 ± 1.4 versus 0.8 ± 0.2 ml, p<0.001). In addition, furo/cap-treated rats consumed substantial amounts of 1.5% NaCl solution compared with controls during this three hour time period (F(1,112) = 9.0, p<0.01; 5.7 ± 1.5 versus 0.7 ± 0.2 ml, p<0.001). The time point at which the furo/cap group intake became significantly elevated compared with the control group was 45 min for water intake (p<0.01) and 60 min for sodium intake (p<0.05) after the captopril injection.
Experiment 2A verified that furo/cap-induced water and sodium ingestion could be attributed, at least in part, to AT1Rs. In particular, rats were pretreated centrally with the AT1R
antagonist irbesartan (200 ng/ul) 15 min before furo/cap treatment (28) . A two-way ANOVA established a main effect of irbesartan on furo/cap induced water intake compared to furo/cap controls (F(1,275) = 11.2, p<0.01). A similar main effect occurred with irbesartan treatment and furo/cap-induced sodium intake (F(1,270) = 9.2, p<0.01). As shown in Figure 4A , irbesartan pretreatment decreased furo/cap-induced water intake by 50% over 90 minutes (5.8 ± 0.6 versus 2.9 ± 0.5 ml, p<0.001), first becoming significant at 45 minutes (p<0.001). Sodium intake was reduced by 56% at 90 minutes (4.6 ± 0.6 versus 2.0 ± 0.5 ml, p<0.001), first becoming significantly attenuated at 45 minutes (p<0.01). This level of suppression of furo/cap-induced water and sodium intake by an AT1R antagonist is consistent with previous findings (19) .
Next, we investigated whether furo/cap-induced water and sodium ingestion could be attributed, at least in part, to p44/42 MAPK signalling. In particular, rats were pretreated centrally with the MEK inhibitor U0126 15 min before the furo/cap treatment. The dose of U0126 was chosen based on previous efficacy (15) , and was validated in our Experiment 1. A two-way ANOVA did not reveal a main effect of U0126 on furo/cap-induced water intake compared to controls (F(1,275) = 2.5, p = 0.1). However, there was a significant interaction between treatment and time (p<0.01). U0126 decreased furo/cap-induced water intake by 30% at 90 minutes (5.8 ± 0.6 versus 4.1 ± 0.5 ml, p< 0.01), as shown in Figure 4A . A two-way ANOVA revealed a main effect of U0126 on furo/cap-induced sodium intake (F(1,280) = 13.0, p<0.001). U0126 reduced sodium intake by 60% (4.5 ± 0.6 versus 1.8 ± 0.5 ml, p < 0.001), first becoming significant at 30 min (p<0.05). Urine volume measurement confirmed that neither irbesartan or U0126 pretreatment the interfered with the diuretic effectiveness of the furo/cap treatment (12.3 ± 0.9 versus 12.4 ± 1.4 versus 14.0 ml, respectively; data not shown).
Previous work that suggested that p44/42 MAPK signalling mediates AngII-induced sodium appetite but not thirst; however, we observed a reduction in water intake in the U0126-treated animals, albeit not until the 90-min time point. We reasoned that this delayed suppression of water intake was an artefact of the two-bottle test, given that consumption of hypertonic saline would provide an osmotic stimulus for water intake. Thus, as U0126 suppresses sodium ingestion, it may indirectly effect to reduce water intake. This interpretation of the data is supported by the fact that U0126 suppressed sodium intake at 30 min, and subsequently reduced water intake at 90 min. To test this hypothesis, the effect of U0126 was examined in a single-bottle test. In this case, a two-way ANOVA revealed that water intake was not significantly decreased with U0126 In Experiment 3B, rats were pretreated centrally with either vehicle or U0126 followed by AngII (20 ng). Two or fifteen minutes after treatment, plasma AVP differed between the groups (Figure 6 ; ANOVA (F(2,38) = 5.6, p<0.01). Given that there were no significant differences between the two and 15 min time points within each treatment group, these data were combined.
Post-hoc analysis indicated that AngII treatment stimulated AVP secretion compared with vehicle treatment (2.5 ± 0.3 versus 1.5 ± 0.2 pg/ml, p<0.01). This level of AngII-induced AVP secretion is consistent with previous findings (29) . However, when animals were pretreated with U0126, the AngII-induced AVP secretion was not significantly different than when AngII was given alone MAPK activation by AngII, they did not show its reduction by MEK inhibitor U0126 in relevant brain regions (15, 16) . The present studies demonstrate that furo/cap induces p44/42 MAPK activation in relevant forebrain areas, and that our doses of central irbesartan and U0126 restore phosphor p44/42 MAPK to control levels. The furo/cap treatment produces high levels of circulating renin and angiotensin I, and central AT1R appears to mediate a large proportion of the observed water and sodium ingestion (19, 30) . The present results further support the notion that AT1R-p44/42 MAPK activation is responsible for the increase in sodium appetite observed in our experiments, and that the reduction of the behaviour by U0126 is due to decreased p44/42 MAPK activation in relevant AT1R containing brain regions. Moreover, our studies provided an additional control to examine the unique role of p44/42 MAPK in sodium appetite through use of a single water bottle test.
Nevertheless, our studies present their own limitations. For example, AngII levels in the brain may be unusually elevated by the peripheral blockade of angiotensin I conversion using the furo/cap model. However, in this protocol AngII production is constrained by physiological availability of the prohormone (19) . Another consideration is that furo/cap treatment may activate other interoceptive systems apart from the renin-angiotensin-aldosterone system. For example, low-and high-pressure baroreceptors would detect the diuresis-induced loss of blood volume and pressure, respectively, and relay this information to brainstem structures that may promote thirst, Studying the signalling molecules involved in the central actions of AngII is the first step to understanding how central AngII exerts its physiological effects, but much remains to be uncovered about the cellular mechanisms by which they mediate these actions. For example, there are several plausible mechanisms by which p44/42 MAPK may mediate sodium appetite in the brain. One possibility is that AngII-MAPK signalling elicits sodium appetite by changing neuronal excitability in circumventricular neurones or forebrain integration sites that project to motor generators involved in salt ingestive behaviour (4, 34) . This rapid effect on synaptic transmission could explain the relatively fast time course of furo/cap-induced sodium appetite (35) .
Alternatively, p44/42 MAPK may be involved in long-term gene transcription and protein synthesis for sodium and potassium channel subunits or AT1R. For example, MAPK up-regulates AT1R in the SFO and PVN, and increased levels of AngII binding to its receptor may explain the robust sodium appetite, although not the lack of p44/42 MAPK-mediated water ingestion (14) .
Other downstream consequences of p44/42 MAPK activation include rearrangements of the cytoskeleton, which could include structural neural plasticity (36, 37) . This mechanism is highlighted in a study by Swank and Sweatt, which found that p44/42 MAPK activation is important for plasticity in taste learning (38) . Other research has demonstrated that sodium appetite is associated with dendritic growth and the development of dendritic spines in the nucleus accumbens (39 (40) . An important avenue for future investigation is to determine the locus within the network of AngII-modulated neural circuitry wherein sodium appetite and sympathetic activity share a common dependence on p44/42 MAPK activation.
Another key question to address is the effect of elevated p44/42 MAPK activity in specific brain regions on the many central actions of AngII.
In summary, these studies provide new evidence that the diverse effects of central AngII rely on divergent signalling mechanisms. More specifically, we found that sodium appetite requires p44/42 MAPK activation, whereas thirst and neurohypophysial hormone secretion do not.
It will be important for future studies to assess the role of both p44/42 MAPK and other MAPK kinases in other central AT1R actions that remain undefined, such as hypothalamic-pituitaryadrenal activation. Moreover, it will be critical to find the downstream targets of MAPK and determine the cellular mechanism of AngII in exerting these central effects.
Perspectives
Elements of the renin-angiotensin-aldosterone system are frequently implicated in the pathogenesis of hypertension, although the cause of hypertension is often unknown (7).
Hypertension is a common and serious health concern (41). One in three adults have chronically elevated blood pressure, which shortens a person's life span by three to five years (42) . The identification of signalling-selective subsets of AngII action in the brain presents an opportunity to more precisely target central pathways that regulate blood pressure (43, 44) . Furo/Cap-induced AVP and OT secretion was not diminished with either the AT1R antagonist
